InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

InMed Pharmaceuticals has reported Finished Goods for 4 years, with the latest figure at $378636.0 in Q4 2025.

• For the quarter ending Q4 2025, Finished Goods fell 43.92% year-over-year to $378636.0; the trailing twelve-month figure through Dec 2025 stood at $378636.0 (down 43.92% YoY), and the FY2025 full-year result was $676178.0, down 19.58% from the prior year.
• Finished Goods for Q4 2025 stood at $378636.0, up from $295809.0 in the prior quarter.
• The five-year high for Finished Goods was $927182.0 in Q3 2024, with the low at $231956.0 in Q1 2025.
• Historically, Finished Goods has averaged $596273.0 across 4 years, with a median of $582161.0 in 2022.
• Annual changes were most pronounced in 2023 — Finished Goods surged 88.73% — and 2025, when it tumbled 68.1%.
• InMed Pharmaceuticals' Finished Goods stood at $605956.0 in 2022, then slipped by 7.94% to $557859.0 in 2023, then advanced by 21.03% to $675164.0 in 2024, then plunged by 43.92% to $378636.0 in 2025.
• The last three Finished Goods figures came in at $378636.0 (Q4 2025), $295809.0 (Q3 2025), and $676178.0 (Q2 2025), per Business Quant data.